Vertex Pharma bring in new CFO, shares rise

pharmafile | September 7, 2017 | Appointment | |  Ironwood Pharmaceuticals, Vertex pharmaceuticals, biotech, drugs, pharma, pharmaceutical 

Vertex Pharmaceuticals announced the appointment of J&J veteran, Tom Graney, as Senior Vice President and Chief Financial Officer. Graney will join the company on 13 September, after departing Ironwood Pharmaceuticals for the role. The esteem with which Graney is held saw shares immediately rise on the release of the news for Vertex by 1.2% and fall for Ironwood by close to 2%.

At Ironwood, he held the role of CFO and Senior Vice President of Finance and Corporate Strategy. Prior to this, he held numerous roles across the Johnson & Johnson’s franchise in his 20-year career at the company; he held roles at the pharma giant that include being the Finance Director for Janssen in the UK, Ireland and Africa. He was also CFO for the North American arm of the Janssen business, rising to VP of Finance and the Global Supply Chain at the overall J&J business.

“I am thrilled to take on this important role with Vertex, a company that I have long admired for its unwavering commitment to patients and to discovering, developing and commercializing transformative medicines for people with serious and life-threatening diseases,” said Graney.

“As Vertex continues its evolution to be a leading global biotech, it is critical that we continue to build a strong and experienced leadership team,” said Ian Smith, Executive Vice President and Chief Operating Officer of Vertex. “Tom has the ideal blend of financial acumen, leadership skills, and industry experience that will be important as Vertex grows and expands as a global company.”

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content